cancer, immunology

A new platform enables screening a wide range of combination anticancer therapeutics in a matter of days, which may translate to personalized therapeutic regimens for patients in less time.

Heated gold nanoparticles unleash the therapeutic activity of engineered CAR T cells.

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.

Meet some of the people featured in the April 2021 issue of The Scientist.

A mutant protein called Siglec-XII may promote carcinoma progression in humans, but inactivation of its gene seems to avoid the problem, according to a study.

From his student days in veterinary medicine in Ethiopia to running a lab on metastasis at MD Anderson Cancer Center, Debeb has a passion for understanding how living things work.

A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.

Cancer therapies could potentially be more effective if their development took into account the cells that give rise to tumor-fighting cells.

Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.

The Oxford researcher’s work on lipid and peptide antigens revealed key mechanisms in inflammation, immunotherapy, and vaccination, which are being pursued in clinical trial treatments.

While neutrophil extracellular traps help guard the body from infection, they also can contribute to a range of diseases.

The Johns Hopkins University researcher’s work helped solidify the link between human papillomavirus and cervical cancer, leading to the approval of the HPV vaccine in 2006.

Research in mice and humans is beginning to establish a link between the composition of microbes in the gut and immune responses to tumor cells, but the mechanisms are not yet clear.